Molecular Cancer Therapeutics 2022 May 2 [Link] Raffit Hassan, Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjistha Sengupta, Markku Miettinen, Nan Li, Ira Pastan, Mitchell Ho Abstract Mesothelin targeting CAR T cells have limited activity in patients. In this study, we sought to determine if efficacy of anti-mesothelin CAR T…

Read More

Oncology Letters 2022 June [Link] Takahiro Kambara, Vishwa Jeet Amatya, Kei Kushitani, Yutaro Fujii, Ihiro Endo, Yukio Takeshima Abstract Pleural malignant mesothelioma is a malignant tumor with a poor prognosis that is strongly associated with asbestos exposure during its development. Because there is no adequate treatment for malignant mesothelioma, investigation of its molecular mechanism is…

Read More

Biomaterials 2022 April 20 [Link] Robert C Sabatelle, Rong Liu, Yin P Hung, Eric Bressler, Eliza J Neal, Andrew Martin, Iriny Ekladious, Mark W Grinstaff, Yolonda L Colson Abstract Peritoneal mesothelioma is an aggressive disease with a median survival of under three years, due to a lack of effective treatment options. Mesothelioma is traditionally considered…

Read More

The Journal of Surgical Research 2022 April 27 [Link] Victor P Gazivoda, Aaron W Kangas-Dick, Alissa A Greenbaum, Joshua Roshal, Chunxia Chen, Dirk F Moore, Russell C Langan, Timothy J Kennedy, Christine Minerowicz, H Richard Alexander Abstract Introduction: Frequency of PD-L1 expression and the role of immunotherapy in malignant peritoneal mesothelioma (MPM) have not been…

Read More

Journal of Thoracic Oncology 2022 April 27 [Link] Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y C Gary Lee, Ian M Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe Abstract Introduction: Pleural mesothelioma (PM) is an aggressive…

Read More

Journal of Thoracic Oncology 2022 May [Link] Jennifer G Whisenant, Javier Baena, Alessio Cortellini, Li-Ching Huang, Giuseppe Lo Russo, Luca Porcu, Selina K Wong, Christine M Bestvina, Matthew D Hellmann, Elisa Roca, Hira Rizvi, Isabelle Monnet, Amel Boudjemaa, Jacobo Rogado, Giulia Pasello, Natasha B Leighl, Oscar Arrieta, Avinash Aujayeb, Ullas Batra, Ahmed Y Azzam, Mojca…

Read More

Legal Medicine 2022 April 22 [Link] Francesca Maghin, Anna Antonietti, Nicoletta Cerri, Liliana Maria Lancini, Andrea Maccarinelli, Samuele Manzoni, Mario Restori, Matteo Rota, Daniela Ruffini, Andrea Verzeletti, Adelaide Conti Abstract Introduction: This study evaluates the assessment protocol that allows the correlation between the development of mesothelioma to a specific exposure, with particular focus on investigations…

Read More

Virchows Archiv 2022 April 24 [Link] Francesca Napoli, Ida Rapa, Stefania Izzo, Angelica Rigutto, Roberta Libener, Chiara Riganti, Paolo Bironzo, Riccardo Taulli, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract The standard front-line treatment for pleural mesothelioma (PM) is pemetrexed-based chemotherapy, whose major target is thymidylate synthase (TS). In several cancer models, miR-215 and…

Read More

Cancers 2022 April 16 [Link] Tugce Kutuk, Haley Appel, Maria Carolina Avendano, Federico Albrecht, Paul Kaywin, Suyen Ramos, Melanie E Suarez-Murias, Minesh P Mehta, Rupesh Kotecha Abstract Purpose: The objectives of this study were to evaluate the implementation, device usage rates, clinical outcomes, and treatment-related toxicities associated with TTFields and pemetrexed plus platinum-based chemotherapy in…

Read More

Histopathology 2022 April 23 [Link] William J Anderson, Lynette M Sholl, Christopher D M Fletcher, Stephanie Schulte, Li Juan Wang, Fiona M Maclean, Michelle S Hirsch Abstract Aims: Malignant mesothelioma (MM) of the tunica vaginalis (TV) is a rare and aggressive tumor, and the molecular features and staining profile with contemporary immunohistochemical (IHC) biomarkers are…

Read More